Drug-induced interstitial lung disease in molecular targeted therapies: High-resolution CT findings

International Journal of Clinical Oncology

Volumn 17, Issue 6, 2012, Pages 542-550

  Sakai, Fumikazu ^a   Johkoh, Takeshi ^b   Kusumoto, Masahiko ^c   Arakawa, Hiroaki ^d   Takahashi, Masahiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

CT; Drug; Lung injury

Indexed keywords

AMIODARONE; ANTIRHEUMATIC AGENT; CETUXIMAB; CRIZOTINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TEMSIROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

BACTERIAL PNEUMONIA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; COLORECTAL CARCINOMA; COMORBIDITY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE ALVEOLAR DAMAGE; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY PNEUMONIA; IMAGE ANALYSIS; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LOEFFLER PNEUMONIA; LOW DRUG DOSE; LUNG CANCER; LUNG DISEASE; LUNG INJURY; MOLECULARLY TARGETED THERAPY; ORGANIZING PNEUMONIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMOKING;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES, INTERSTITIAL; MOLECULAR TARGETED THERAPY; PULMONARY FIBROSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880698507     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0489-2     Document Type: Review

References (35)

1. Camus P, Fanton A, Bonniaud P et al (2004) Interstitial lung disease induced by drug and radiation. Respiration 71:301-326
2. Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348-1357
3. Gotoh A, Ohyashiki K, Oshimi K et al (2006) Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int J Hematol 84:406-412
4. Sakai F, Noma S, Kurihara Y et al (2005) Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 15:173-179
5. Inoue A, Saijo Y, Maemondo M et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139
6. Japanese Respiratory Society (2012) Guideline for the diagnosis and treatment of drug-induced lung injury. Medical Review Publishers, Tokyo
7. Alarcón GS, Kremer JM, Macaluso M et al (1997) Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter case-control study. Methotrexate-Lung Study Group. Ann Intern Med 127:356-364
8. Erasmus JJ, McAdams HP, Rossi SE (2002) Drug-induced lung injury. Semin Roentgenol 37:72-81
9. Akira M, Ishikawa H, Yamamoto S (2002) Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology 224:852-860
10. Rossi SE, Erasmus JJ, McAdams HP et al (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20:1245-1259
11. Cleverley JR, Screaton NJ, Hiorns MP et al (2002) Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 57:292-299
12. Ichikado K, Suga M, Gushima M et al (2000) Hyperoxia-induced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings. Radiology 216:531-538
13. Tomiyama N, Müller NL, Johkoh T et al (2001) Acute respiratory distress syndrome and acute interstitial pneumonia: comparison of thin-section CT findings. J Comput Assist Tomogr 25:28-33
14. Ichikado K, Suga M, Muranaka H et al (2006) Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. Radiology 238:321-329
15. Imokawa S, Colby TV, Leslie KO et al (2000) Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 15:373-381
16. Arakawa H, Yamasaki M, Kurihara Y et al (2003) Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imag 18:231-236
17. Tokuda H, Sakai F, Yamada H et al (2008) Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 47:915-923
18. Souza CA, Müller NL, Johkoh T et al (2006) Drug-induced eosinophilic pneumonia: high-resolution CT findings in 14 patients. AJR Am J Roentogenol 186:368-373
19. Ben m'rad M, Leclerc-Mercier S, Blanche P et al (2009) Drug-induced hypersensitivity syndrome: clinical and biologic disease pattern in 24 patients. Medicine (Baltim) 88:131-140
20. Cameron RJ, Kolbe J, Wilsher ML et al (2000) Bronchiolitis obliterans organizing pneumonia associated with the use of nitrofurantoin. Thorax 55:249-251
21. Kameda H, Tokuda H, Sakai F et al (2011) Clinical and radiological features of acute-onset diffuse interstitial diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 50:305-313
22. Komano Y, Harigai M, Koike R et al (2009) Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61:305-312
23. Tanaka M, Sakai R, Koike R et al. (2012) Pneumocystis jiroveci pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol (Epub ahead of print)
24. Ohnishi K, Sakai F, Kudoh S et al (2006) Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20:1162-1164
25. Merc-Serono Co. Ltd., Bristol-Meyers Co., Ltd. (2009) Post-marketing survey of adverse reaction of Erbitux™ (cetuximab) injection 100 mg. Tokyo
26. Takeda Pharmaceutical Co., Ltd. (2001) Special post-marketing survey of adverse reaction of Vectebix™ (panitumab) 100 mg injection. Tokyo
27. Hagiwara K, Sato T, Takagi-Kobayashi S et al (2007) Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 34:1151-1154
28. Novartis Pharma (2011) Result of drug-induced interstitial pneumonia in special post-marketing survey of Affinitiol™ (everolimus) tablet
29. Pfizer Co., Ltd. (2011) Guide of appropriate use of Tricel™ (temsirolius) injection 25 mg
30. Maroto JP, Hudes G, Dutcher JP et al (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29:1750-1756
31. White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396-403
32. Champion L, Stern M, Israël-Biet D et al (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144:505-509
33. Koike R, Tanaka M, Komano Y et al (2011) Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients. Pulm Pharmacol Ther 24:401-406
34. Kennedy JI, Myers JL, Plumb VJ et al (1987) Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations. Arch Intern Med 147:50-55
35. Kuhlman JE, Scatarige JC, Fishman EK et al (1987) CT demonstration of high attenuation pleural-parenchymal lesions due to amiodarone therapy. J Comput Assist Tomogr 11:160-162